Becaris
Browse

Supplementary tables: Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma

Download (41.76 kB)
dataset
posted on 2024-05-03, 15:38 authored by Sally D Miller, Greta Lozano-Ortega, Alex Mutebi, Owanate Briggs, Kavita Sail, Brian Elliott, Anupama Kalsekar

These are peer-reviewed supplementary materials for the article 'Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma' published in the Journal of Comparative Effectiveness Research.

  • Supplementary Table 1: PICOS criteria defining the scope of the current SLR
  • Supplementary Table 2: Search strategies
  • Supplementary table 3: MINORS assessments
  • Supplementary table 4: Cochrane Risk of Bias 2 assessments

Aim: To evaluate trials of systemic therapies in transplant-ineligible or -experienced, relapsed/refractory diffuse large-B cell lymphoma and the impact of patient characteristics on overall response rate (ORR). Patients & methods: Systematically reviewed multiple databases through 22 July 2021. Analyzed variations in patient characteristics and their relationship with ORR across trials. Results: Among 17 included trials, key patient characteristics varied substantially: primary refractory (0–69%), refractory to last line of therapy (LOT) (12–100%), ≥2 prior LOTs (14–100%), ≥3 prior LOTs (0–64%), IPI ≥3 (23–73%), tumor stage III/IV (50–90%) and median age (56–74 years). ORRs varied substantially (25–83%), correlating with these characteristics. Conclusion: Differences in patient characteristics significantly contribute to the variability in ORR across these trials and should be considered when contextualizing efficacy data.

History

Usage metrics

    Becaris

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC